Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status:
Suspended
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This trial is divided into two parts, a dose-escalation study (phase 1) and a randomized
study (phase 2).
The purpose of the dose-escalation study (phase 1) is to determine the safety, maximum
tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in
subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation
therapy and temozolomide (TMZ).
The purpose of the randomized study (phase 2) is to determine the safety and efficacy of the
phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects
who have GBM that has progressed following prior radiation therapy and TMZ.